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Background and purpose   The remodeling of morselized bone 
grafts in revision surgery can be enhanced by an anabolic sub-
stance such as a bone morphogenetic protein (BMP). On the 
other hand, BMPs boost catabolism and might cause a prema-
ture resorption, both of the graft and of the new-formed bone. 
Bisphosphonates inactivate osteoclasts and can be used to control 
the resorption. We studied a combination of both drugs as a local 
admix to a cancellous allograft.
Methods   Cancellous bone allografts were harvested and 
freeze-dried. Either saline, BMP-7, the bisphosphonate zoledro-
nate, or a combination of BMP-7 and zoledronate were added in 
solution. The grafts were placed in bone conduction chambers 
and implanted in the proximal tibia of 34 rats. The grafts were 
harvested after 6 weeks and evaluated by histomorphometry. 
Results   Bone volume/total volume (BV/TV) was 50% in the 
grafts treated with the combination of BMP-7 and zoledronate 
and 16% in the saline controls (p < 0.001). In the zoledronate 
group BV/TV was 56%, and in the BMP group it was 14%. The 
ingrowth distance of new bone into the graft was 3.5 mm for the 
combination of BMP-7 and zoledronate and 2.6 mm in the saline 
control (p = 0.002). The net amount of retained remodeled bone 
was more than 4 times higher when BMP-7 and zoledronate were 
combined than in the controls.
Interpretation   An anabolic drug like BMP-7 can be combined 
with an anti-catabolic bisphosphonate as local bone graft adjunct, 
and the combination increases the amount of remaining bone 
after remodeling is complete. 
 
The clinical results of revision hip arthroplasties using mor-
selized and impacted allografts are good (Ornstein et al. 2009). 
There are indications from radiostereometric studies that the 
graft does not always provide full stability during remodeling, 
and a continuous migration of the cup has been shown after as 
long as 5 years in 5/17 patients (Ornstein et al. 2006). Mor-
selized and impacted allograft is by definition a necrotic mate-
rial, but will partially remodel and incorporate into a new bony 
structure. This process involves a catabolic part with resorp-
tion of the dead bone graft by osteoclasts and an anabolic part 
with osteoblasts forming a new trabecular structure (van der 
Donk et al. 2002). Both the anabolic and catabolic processes 
can be manipulated by drugs (Little et al. 2007). 
Bone morphogenetic proteins (BMPs) stimulate bone for-
mation and bone allograft remodeling, and have been used 
to increase the remodeling of morselized and impacted bone 
graft both in animal models (McGee et al. 2004) and in human 
hip revisions (Kärrholm et al. 2006). However, BMPs also 
stimulate osteoclasts (Okamoto et al. 2006) and an increased 
resorption may cause a reduced load bearing capacity of the 
remodeling graft, resulting in mechanical failure (Tägil et al. 
2003, Kärrholm et al. 2006). In contrast, bone graft that is not 
remodeled retains its load-bearing capacity (Parks and Engh 
1997) but with time will be prone to fatigue fractures, which 
could weaken the implant fixation. We believe that remodel-
ing of the bone graft is advantageous, but only if the bone 
can maintain its mechanical properties during the remodeling. 
Thus, when increased anabolism is desired in a mechanically 
loaded bone graft, a bisphosphonate might be used in addition 
to the bone anabolic BMP to control the resorption (Jeppsson 
et al. 2003). 
Bisphosphonates have a strong affinity for calcium phos-
phate and are chemically bonded to the bone mineral (Rogers 
et al. 2000) regardless of whether they are administered sys-
temically (Tägil et al. 2006) or locally (Aspenberg and Åstrand 
2002). In consequence, a graft can be treated locally by simply 
soaking it in a bisphosphonate solution before implantation, 
thereby protecting the new-forming bone from the increased 
resorption caused by the BMP. We investigated whether it 
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graft by adding BMP-7 locally and at the same time protect 
the new-forming bone from resorption by local treatment with 
zoledronate, a potent third-generation bisphosphonate
Methods
The chamber
We used a rat model with a cancellous allograft that remodels 
in vivo in a bone conduction chamber (BCC) (Aspenberg and 
Wang 1993) (Figure 1). The chamber consists of a threaded 
titanium cylinder, formed from 2 half-cylinders that are kept 
together by a hexagonal screw cap. The interior of the cham-
ber is 7 mm long with a diameter of 2 mm. One end of the 
implant is screwed into the proximal tibia. At this end, there 
are 2 ingrowth openings each measuring 0.75 mm2, where 
tissue can grow in from the subcortical bone. 
Grafts
Pairs of structurally intact cancellous bone grafts were 
obtained from 34 female Sprague-Dawley rats (200 g; Taconic 
M&B A/S, Ry, Denmark). A cylindrical bone rod with a diam-
eter of 2 mm was harvested in the axial direction from the 
knee joint with a hole cutter and the epiphysis was discarded. 
The rods were approximately 4–5 mm long. The grafts were 
kept sterile and freeze-dried for 24 h. At surgery, the grafts 
were thawed, placed in the chambers, and soaked with 8 µL of 
experimental solution or saline.
Surgical procedure
34 male Sprague-Dawley rats (321–355 g; Taconic M&B) 
received bilateral chambers. The rats were anesthetized with 
diazepam and pentobarbitalnatrium. Antibiotic prophylaxis 
was given as 12.5 mg dihydrostreptomycin and 10 mg pro-
caine benzylpenicillin. Under aseptic conditions, a longitu-
dinal incision was made over the anteromedial aspect of the 
proximal tibial metaphysis. Holes were made with a drill and 
the chambers were screwed into position with the ingrowth 
holes situated subcortically. The wounds were closed, leaving 
the entire chamber subcutaneous. Postoperatively, analgesic 
was given as 4.5 µg buprenorphine subcutaneously. All animal 
handling was approved by the regional animal research ethics 
committee.
Drug administration
BMP-7 (Osigraft; Stryker Biotech, Malmö, Sweden) was 
obtained as a powder with a concentration of 3.5 mg/1 g 
bovine collagen. The powder was diluted in saline to a concen-
tration corresponding to 2 µg BMP-7 per graft. This amount 
corresponds to a clinical equivalent of 1 vial of BMP-7 to 1 
morselized femoral head. Zoledronate (Zometa; Novartis, 
North Ryde, NSW, Australia) was obtained as a powder and 
was diluted in saline to a concentration corresponding to 4 µg 
zoledronate per graft. Immediately before insertion, each graft 
was soaked with 8 µL of either saline, BMP-7, zoledronate, or 
a combination of the latter two. To avoid a systemic effect of 
the bisphosphonate, the rats were randomized into 2 groups. 
One group received grafts treated with BMP-7 in the right 
leg and saline-treated in the left. In the other group, the rats 
received chambers containing both BMP-7 and zoledronate in 
the right leg and zoledronate alone in the left. 
Evaluation
The rats were killed after 6 weeks and the contents of the 
chambers were prepared for decalcified histology. The speci-
mens were fixed in 4% formaldehyde, decalcified, dehydrated, 
and embedded in paraffin. They were cut parallel to the long 
axis of the chamber with a microtome and stained with hema-
toxylin and eosin. 3 sections from the middle of the speci-
mens, each at 300 µm distance from the previous one, were 
used for histological and histomorphometric analyses. All 
slides in each experiment were investigated blind in random 
order. 
The area of the newly formed remodeled bone in each slide 
was measured using a digital system and a digitizer (Video-
plan; Kontron Bildanalyse, Esching, Germany) by measuring 
the area at 20× screen magnification formed by the bottom 
and sides of the chamber and the distal bone ingrowth fron-
tier. This new-formed remodeled bone area includes the 
new-formed marrow cavity within the graft as well as graft 
remnants that had been surrounded by new bone. The bone 
ingrowth frontier, the border between new-formed remodeled 
and non-remodeled bone, is clear (Figures 1 and 2). To com-
pensate for a variable ingrowth distance of the bone ingrowth 
frontier into the graft, however, the mean bone ingrowth dis-
tance in each slide was calculated by dividing the area of the 
Figure 1. A. The bone conduction chamber with a freeze-dried graft. 
The graft is placed in the chamber and mesenchymal tissue grows 
in from the bottom upwards into the bone graft, which subsequently 
remodels. B. Histological picture (hematoxylin and eosin, ×20) of an 
untreated graft after 6 weeks in the chamber. Ingrowth occurs from the 
bottom of the picture as the graft is revascularized. Bone formation lags 
behind the vascular ingrowth and starts with an osteoclastic resorp-
tion of the bone graft, followed by a front of new forming bone. In this 
unloaded model, the new bone is almost entirely resorbed and finally 
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new-formed remodeled bone by the width of the specimen. 
The mean bone ingrowth distance for each animal was used as 
a final surrogate variable of bone anabolism, i.e. how far into 
the graft the remodeling took place. 
The amount of remaining bone within the new-formed 
remodeled bone, behind the bone ingrowth frontier, was used 
as a surrogate variable of bone catabolism. A volume frac-
tion estimation, equivalent to and expressed as BV/TV (bone 
volume/total volume), was made of both the remaining dead 
graft and living new-formed bone within this area by a point-
count method ad modum Cavalieri, using a Merz grid ocular 
lens (Merz and Schenk 1970) with 6 × 6 crossing lines form-
ing 36 points. Multiple sections of the new-formed remodeled 
bone of each graft were analyzed at 40× magnification using 
the point count method, from the bottom of the chamber to the 
bone ingrowth frontier. A distinction was made between dead 
graft bone and new living bone by evaluating matrix staining 
and the presence of osteocytes. The frequency of the crossings 
covering graft and newly formed bone tissue was recorded and 
expressed as a percentage of the total area measured (bone 
area/total area). 
Arithmetically, the volume of the new-formed remodeled 
bone in the chamber can be expressed as a function of the 
mean bone ingrowth distance into the graft × π × r² where r is 
the radius of the chamber (1 mm). By multiplying BV/TV by 
the volume, we can calculate the total or relative amount of the 
retained new-formed and non-resorbed bone graft. 
Statistics
Results were analyzed non-parametrically, as normal distribu-
tion could not be assumed, using the Mann-Whitney U-test. 
We used SPSS software version 16.0 for Windows.
Results
No wound infections occurred. 1 rat receiving zoledronate 
died during anesthesia. Tibial fractures occurred in 2 rats in 
the BMP-7 group during surgery and these were excluded. 1 
chamber in the zoledronate group loosened and was excluded, 
thus leaving 17 grafts in the control group, 15 in the BMP-7 
group, 15 in the zoledronate group, and 16 in the BMP-7 + 
zoledronate group.
Histology
In all chambers, almost the entire graft had been revascular-
ized at harvest. New bone had penetrated the graft and had 
formed a bone ingrowth frontier at varying distances into the 
graft (Figures 1 and 2). The frontier appeared to have advanced 
further into the grafts treated with BMP-7 (Figures 2b and 2d). 
Behind the frontier, the grafts were resorbed to varying extents 
and hematogenous or fat cell-rich bone marrow had formed. 
In the controls and BMP-7 group (Figures 2a and 2b), the 
grafts had been resorbed almost entirely. In contrast, the zole-
dronate-treated grafts appeared intact, with new bone formed 
Figure 2. Histological specimens representing the 4 treatment groups after 6 weeks in the chamber (hema-
toxylin and eosin). Host tissue enters the graft through holes in the bottom of the chamber and ingrowth/
remodeling occurs from the bottom upwards. The front of bone ingrowth is marked with a black line. A. 
Saline-treated chamber specimen with remodeled bone graft below the arrows. Most of the newly formed 
bone below the bone ingrowth front has already been remodeled into a fatty cell marrow. B. In the BMP-
7-treated specimens, the bone ingrowth front has reached further into the graft than in the controls. C. 
In the zoledronate-treated specimens, the remodeled bone below the ingrowth front has a BV/TV (bone 
volume/total volume) value about 3 times higher than in the controls. D. Here, both BMP-7 and zoledronate 
were given and both the ingrowth distance and bone retention are increased compared to the control. The 
images have been chosen to be representative of the group median in terms of bone ingrowth and BV/
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around the graft trabeculae (Figures 2c and 2d). Both old graft 
bone and newly formed bone was retained in the zoledronate-
treated samples. The difference in bone density was clearly 
visible. In all cases, vascularized fibrous tissue had penetrated 
further into the chamber ahead of the new bone.
Histomorphometry
Both the group treated with zoledronate and the group treated 
with the combination of zoledronate and BMP-7 showed sta-
tistically significantly higher BV/TV values than the saline 
control and BMP-7 alone (Table 1). The relative proportion 
of old graft bone (dead bone/total bone) was 20% and 22% 
in the 2 zoledronate-treated groups, and 12% and 14% in the 
control group and the BMP-7-alone group. Bone ingrowth had 
reached further in the grafts treated with the combination of 
zoledronate and BMP-7, compared to zoledronate alone or 
saline (Table 2).
In total, the net amount of remodeled and retained bone in 
the grafts increased to 5.5 mm³ when BMP-7 and zoledronate 
were combined, as compared to 1.3 mm³ in the control, a more 
than fourfold increase. In the zoledronate-alone group the total 
retained bone volume was 4.0 mm³, and in the BMP-7-alone 
group it was 1.3 mm³.
Discussion
In hip revisions using morselized and impacted allograft, the 
remodeling is slow and incomplete (van der Donk et al. 2002, 
Linder 2000). A mixed pattern, with areas of remodeled bone, 
revascularized bone without remodeling, and inert, non-revas-
cularized and non-remodeled bone is found histologically 
(Linder 2000). These histological findings are similar to the 
various areas within the bone chamber (Figures 1 and 2). To 
improve graft remodeling, drugs have been used to speed up 
the process and quicker form a living support to the implant 
and cement construct (McGee et al. 2004, Kärrholm et al. 
2006). BMP-7 has been shown to stimulate graft remodeling 
in several experimental studies but—something that is per-
haps less well known—it also appears to activate osteoclasts, 
leading to an increased amount of resorption (Okamoto et al. 
2006).
In the present rat bone chamber experiment, BMP-7 sped up 
the ingrowth and the remodeling front advanced deeper into the 
graft than it would have without BMP-7. On the other hand, all 
the bone that formed was more or less totally resorbed behind 
the thin new-forming bone front. Since bone strength corre-
lates mainly with BV/TV ratio (Carter and Spengler 1978); 
a full remodeling, although achieved earlier due to the BMP, 
may be less advantageous regarding load bearing (Burchardt 
1983). By adding a bisphosphonate, this unwanted resorption 
was controlled, both in the BMP-treated and saline-treated 
grafts. The BV/TV ratio of the remodeled bone increased and 
did so without disturbing the new bone formation, as seen and 
feared for in other studies (Jeppsson et al. 2003, Jakobsen 
et al. 2007, Baas et al. 2008). In the bisphosphonate-treated 
specimens, sometimes the graft bone was not resorbed but was 
instead covered with the new-forming bone, thus forming an 
integrated construct of old and new bone (Figure 3). The com-
bination of an anabolic drug (BMP-7) and an anti-catabolic 
Table 1. The catabolic part of the bone remodeling, illustrated by the BV/TV value (bone volume/total volume; expressed 
as median (range)). BV/TV is mainly influenced by the addition of a bisphosphonate, which stalls catabolism. Com-
parisons are shown unpaired between the right sides, treated with BMP-7 and the left sides, treated with saline, for 
both the zoledronate (ZA) group and the control group. The amount of new-formed bone on the old graft is given for 
comparison
    Saline  ZA   p-value  BMP-7  BMP-7 + ZA  p-value
    (n = 17)  (n = 15)    (n = 15)  (n = 16)
BV/TV, %   16 (10–40)  56 (37–68)  < 0.001  14 (2–54)  50 (40–57) a  < 0.001
  New-formed   14 (7–34)  47 (23–58)    11 (2–43)  39 (26–56)
   Retained graft     2 (0–12)  11 (5–17)      2 (0–10)   11 (7–18)
a p < 0.001 vs. control.
Table 2. The anabolic part of the bone remodeling, illustrated by the bone ingrowth distance of new bone into the 
chamber (median (range)). Bone ingrowth distance is mainly influenced by the addition of a bone proliferation and dif-
ferentiation inducer such as BMP-7. Comparisons have been made pairwise (15 complete pairs) between the right side, 
treated with BMP-7, and the left side, treated with saline, for both the zoledronate (ZA) group and the control group
  Saline  BMP-7  p-value  ZA  ZA + BMP-7  p-value
Ingrowth, mm  2.6 (1.5–4.4)  3.0 (1.9–4.4)  0.07  2.3 (1.0–3.5)  3.5 (2.4–5.8) a  < 0.003 
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drug (zoledronate) resulted in both an increased ingrowth 
distance of new bone into the bone graft and a dramatically 
increased BV/TV value. In total, more than 4 times more bone 
was present after remodeling in the chamber when the com-
bination of BMP-7 and zoledronate was used compared to 
saline-treated control graft.
Several advantages can be obtained by combining a locally 
applied BMP with a locally applied bisphosphonate, instead of 
systemic administration. With local administration, the drug is 
added to the graft already during the operation. All of the graft 
will be treated independently of the level of revascularization, 
and all bone binding sites will be saturated with chemically 
bound zoledronate, thus protecting the graft from resorption 
until completely remodeled. With local administration, poor 
patient compliance is avoided (Rabenda et al. 2008). Further-
more, the systemic effects of an intravenous bisphosphonate 
can be avoided and the total dose used kept smaller than with 
systemic treatment.
The bone chamber is a simple model to understand basic 
bone remodeling. Since the remodeling occurs from the 
bottom of the chamber and upwards in a certain sequence, it 
is easy to identify the different and sequential steps of graft 
remodeling.    The chamber does, however, have limitations 
and the results might not be generalizable for clinical use. 
With other animal models, concerns have been raised regard-
ing local treatment (Jakobsen et al. 2007), implying risks of 
an anabolic deficiency caused by the bisphosphonate also 
when combined with BMP. In vitro studies have demonstrated 
that bisphosphonates can inhibit osteoblastic cell metabolism 
(Iwata et al. 2006) and induce apoptosis in a wide range of 
cells, including osteoblasts. In vivo, bisphosphonates in clini-
cally used doses become chemically bound to bone and are 
metabolized almost exclusively by osteoclasts. However, with 
excessive amounts of unbound bisphosphonate released into 
the tissue, an anti-anabolic effect might occur (Schindeler and 
Little 2007). In a canine implant study, 2.5-mm peri-implant 
gaps were filled with impacted bone graft with or without 
bisphosphonate. A reduced degree of mechanical fixation was 
found in the bisphosphonate group due to decreased bone for-
mation and delayed removal of debris (Jakobsen et al. 2007). 
In that study, just as in ours, the graft was not rinsed from 
excessive bisphosphonate fluid before impaction and the 
authors speculated that the reason for the inferior mechani-
cal strength might be due to an unwanted anti-anabolic effect 
on top of the desired anti-catabolic effect. In another study, 
investigating BMP-2 and pamidronate in an impaction graft-
ing model, not only the substances alone but also the combina-
tion was inferior to the saline control as pamidronate virtually 
blocked bone metabolism, even when combined with BMP-2 
(Baas et al. 2008).  
In most previous studies from our laboratory, any excess 
of bisphosphonate has been washed away through rinsing 
of the graft. In the present study, this was not in the proto-
col because rinsing would have washed away the non-binding 
BMP-7, which was also added locally. Thus, high concentra-
tions of zoledronate might have occurred locally, having a 
negative effect on bone formation and bone ingrowth. In the 
zoledronate group, the ingrowth distance appeared somewhat 
shorter (but not statistically significantly so) compared to the 
control group, indicating such a negative effect. The ingrowth 
distance was indeed shorter than all previous pooled chamber 
studies done in our laboratory using systemic bisphospho-
nates. Perhaps local bisphosphonate treatment would impair 
bone formation to a greater extent than systemic, a hypothesis 
that deserves further investigation.
Administration of zoledronate locally increases bone graft 
density after remodeling. It has a low risk of systemic side 
effects but an equivalent effect on resorption compared to 
previous studies using systemic zoledronate (Harding et al. 
2008). There is a risk of reduced bone formation with locally 
administered bisphosphonates, which in our model could 
easily be compensated for by local administration of BMP at 
the same time. However, further investigations must be per-
formed before local treatment can be tried clinically, espe-
cially analysis of whether the mechanical strength is increased 
by the increased bone formation and density. 
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Figure 3. Bisphosphonate-treated specimen to the left (A) and saline-
treated control to the right (B) (hematoxylin and eosin, ×40). A. Note 
how the new-formed bone (NB), identifiable by the existing cell nuclei 
(black arrows), covers the old graft bone (G) with its lost nuclei (white 
arrows). Due to the delayed resorption, an old bone–new bone con-
struct is formed. B. In the saline-treated control, such a construct does 
not form as extensively. The graft bone (G) is resorbed and replaced by 
new bone (NB), which is in turn immediately resorbed, being replaced 
by a hematogenous/fat cell marrow (Ma). 
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